Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

Nitric oxide (NO), a gaseous transmitter extensively present in the human body, regulates
vascular relaxation, immune response, inflammation, neurotransmission, and other crucial …

The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Cancer and chronic infections induce T cell exhaustion, a hypofunctional fate carrying
distinct epigenetic, transcriptomic and metabolic characteristics. However, drivers of …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the
treatment of advanced cancers. However, the tumor microenvironment (TME) functions as a …